Congrats to @DrRanaMcKay @shilpaonc and the entire @COVID19nCCC on this study showing no association between ADT and mortality in men with prostate cancer and #COVID19. @DrChoueiri @PGrivasMDPhD @hemoncwarner @Ecquis https://t.co/gF8Eiej5gV

— Shuchi Gulati MD MSc FACP (@ShuchiGulati) November 16, 2021

These maint trials show benefit of pem isn't exhausted after 4 cycles, that more is better in pts w/o PD, but that doesn't mean some pts wouldn't do just as well w/breaks along the way. We will likely never have trial to test this, but IMO, fair to consider for individual pts. https://t.co/qJ8cucuNMy

— H. Jack West, MD (@JackWestMD) November 18, 2021

#FinancialToxicity is all too common (& if anything it's gotten worse). The median pt on this 2017 study was underinsured, 1 in 6 had HIGH or OVERWHELMING distress, & many faced unexpected costs which was associated w/ ⬇️ willingness to pay for cancer tx. https://t.co/03jvXubc2k pic.twitter.com/qPuMHUePAE

— Fumiko Ladd Chino, MD (@fumikochino) November 18, 2021

FDA approved nab-sirolimus for patients with PEComa. Yet another ultra-rare sarcoma where our understanding of driver alterations led to rational drug testing and regulatory approval. Sarcoma: an ideal field for drug development, given the genetic diversity and unmet medical need

— Patrick Schöffski (@schoffski) November 23, 2021

Amazing line-up of Diversity, Equity, and Inclusion events at #ASH21

Heath Equity Rounds

Anti-Racism Studio

Plenty of abstracts/educational sessions focusing on equity/ disparities

Great to see these topics prioritized at a heavily scientific meeting https://t.co/VkHIupnS2e

— Pat McGann, M.D. (@PTMcGann) November 24, 2021